Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

It would seem CytoDyn has still not learned how to

Message Board Public Reply | Private Reply | Keep | Replies (5)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155042
(Total Views: 1069)
Posted On: 05/25/2021 5:27:41 PM
Posted By: blafarm
It would seem CytoDyn has still not learned how to design a bulletproof protocol -- even in the face of repeated and embarrassing failures.

First of all, neither of these trial are described as "Adaptive Design". Why not?

Moving on, we all know the over/under 65 results from the CD12. Why isn't the Critical protocol optimized to target the cohort we know we can win an approval with?

Do we think they've even included age matching protocols this time around? I somehow doubt it.

And the Moderate protocol -- stop me before I start using foul language.

Really, 350mg? No dose escalation? Who came up with this brilliant idea? Were they just sitting around, trying to figure out how they could handicap and fail another trial?

There isn't a single leronlimab indication that is not improved through the administration of the 700mg dose. There's no reason on earth to design a trial using 350mg -- unless your goal is complete and utter failure. Even the LH trial (which may be characterized as a different disease -- or disease stage) uses 8-consecutive doses of 700mg.

This is clearly not the time to perform cost-benefit trials to determine minimum effective dosages. It is the time to prove to the world, once and for all, that the molecule works at the optimum dose and the optimum frequency -- which we did not do with the CD10.

What exactly is wrong with our team? Do they not understand that we are in "Hail Mary" mode -- and there is absolutely no room for failure?

These morons are going to waste millions of our dollars treating 594 patients with inadequate dosing. Even a child could understand this. I expect the Moderate trial will fail -- just as I expressed concern last July that we'd possibly fail the CD12 due to the 2-dose limitation.

Many of you will remember accusing me as being a short when I expressed that concern. Of course, I'm sure you've now conveniently forgotten your baseless accusations. Isn't human nature wonderful?

It's no wonder a group has formed that wants to remove current management.


(20)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us